Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention.
Rolf P. Kreutz, M. D., FACC, FAHA, FSCAI, Associate Professor of Clinical Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1801 N. Senate Blvd., MPC2, ME400, Indianapolis, IN 46202-1228, USA, Tel.: +1 317 962 0500, E-mail: rkreutz@iu.edu.
Rolf P
RP
Kreutz
Glen
G
Schmeisser
Benjamin
B
Maatman
Andrea
A
Schaffter
Anjan
A
Sinha
Elisabeth
E
von der Lohe
Jeffrey A
JA
Breall
D000368:Aged; D001777:Blood Coagulation; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D003328:Coronary Thrombosis / Q000097:blood / Q000209:etiology; D005260:Female; D005337:Fibrin / Q000378:metabolism*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors; D015607:Stents; D013718:Tensile Strength; D013916:Thrombelastography; D013997:Time Factors; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D005337:Fibrin